Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC).

Jacoby MA, Finn L, Emadi A, Saba NS, Powell BL, Seiter K, Garcia R, Faderl S, Male HJ. Leuk Lymphoma. 2021 May; :1-4.

Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia.

Walker CJ, Mrózek K, Ozer HG, Nicolet D, Kohlschmidt J, Papaioannou D, Genutis LK, Bill M, Powell BL, Uy GL, Kolitz JE, Carroll AJ, Stone RM, Garzon R, Byrd JC, Eisfeld AK, de la Chapelle A, Bloomfield CD. Blood Adv. 2021 03; 5(5):1474-1482.

Efficacy of 10-day decitabine in acute myeloid leukemia.

Bouligny IM, Mehta V, Isom S, Ellis LR, Bhave RR, Howard DS, Lyerly S, Manuel M, Dralle S, Powell BL, Pardee TS. Leuk Res. 2021 Apr; 103:106524.

A Pilot Phase II Study of the Feasibility and Efficacy of Vincristine Sulfate Liposome Injection in Patients With Relapsed or Refractory Acute Myeloid Leukemia.

Seegars MB, Woods R, Ellis LR, Bhave RR, Howard DS, Manuel M, Dralle S, Lyerly S, Powell BL, Pardee TS. J Hematol. 2021 Feb; 10(1):1-7.

SMARCA4 mutations in KRAS-mutant lung adenocarcinoma: a multi-cohort analysis.

Liu L, Ahmed T, Petty WJ, Grant S, Ruiz J, Lycan TW, Topaloglu U, Chou PC, Miller LD, Hawkins GA, Alexander-Miller MA, O'Neill SS, Powell BL, D'Agostino RB, Munden RF, Pasche B, Zhang W. Mol Oncol. 2021 02; 15(2):462-472.

Poor Survival and Differential Impact of Genetic Features of Black Patients with Acute Myeloid Leukemia.

Bhatnagar B, Kohlschmidt J, Mrózek K, Zhao Q, Fisher JL, Nicolet D, Walker CJ, Mims AS, Oakes C, Giacopelli B, Orwick S, Boateng I, Blachly JS, Maharry SE, Carroll AJ, Powell BL, Kolitz JE, Stone RM, Byrd JC, Paskett ED, de la Chapelle A, Garzon R, Eisfeld AK. Cancer Discov. 2021 Mar; 11(3):626-637.